secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2026-07-27T20:31:46+00:00
Accession:  0001628280-26-049822
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology reports record annual revenue of $59.4M; FY2026 operating loss of $1.1M vs prior year income of $4.6M
--------------------------------------------------------------------------------

- Record annual revenue $59.4M, up 4% YoY; Q4 revenue $13.8M, up 12% YoY.
- FY2026 operating loss $1.1M (incl. $1.2M stock comp, $1.4M D&A) vs prior year operating income $4.6M.
- Adjusted EBITDA $1.6M for FY2026, down from $7.1M prior year; Q4 adjusted EBITDA $158K positive.
- Oncology services margin 48% for FY2026 vs 50% prior year; Q4 margin improved to 51% from 41%.
- Cash $4.9M, no debt; continued investment in radiopharmaceuticals, data platform, commercial organization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828026049822/0001628280-26-049822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828026049822/csbr-20260727.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-049822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer